Shares in Argent BioPharma more than doubled on the ASX on Tuesday after it struck a […]
Argent BioPharma Stock Surges on CannEpil Licensing Pact That Clears US$5.5m in Debt
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
Argent BioPharma
ASX
CannEpil
epilepsy
FDA
Mercer Street Global Opportunity Fund
Splash Beverage Group
Related Articles
